MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance

Title:MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance

Volume: 28 Issue: 33

Author(s): Anna Puła, Paweł Robak and Tadeusz Robak*

Affiliation:

• Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz Ul, Ciolkowskiego 2,Poland

Keywords: Bortezomib, drug resistance, epigenetics, microRNA, multiple myeloma, p53, pathogenesis, prognostic markers.

Abstract: Multiple myeloma (MM) is a common malignant hematological malignancy. Recently, interest has grown in the role of non-coding regions in disease pathogenesis. MicroRNAs (miRNAs) are small non-coding RNAs containing 19-25 bases that play a crucial role in messenger RNA silencing and post-transcriptional regulation of gene expression. Several miRNAs demonstrate markedly dysregulated expression in MM, suggesting that they may act as both tumor suppressors and oncogenes. microRNAs are also reportedly involved in the regulation of other epigenetic mechanisms of gene expression. Additionally, some miRNAs have been associated with drug resistance, and therefore a further exploration of their activity may lead to its reversal. Moreover, miRNA expression patterns in either MM cells or serum exosomes have been shown to be good prognostic markers. This review describes the roles of miRNAs in MM and examines their potential to predict MM prognosis and play a role in novel therapeutic strategies.

Cite this article as:

Puła Anna , Robak Paweł and Robak Tadeusz *, MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance, Current Medicinal Chemistry 2021; 28 (33) . https://dx.doi.org/10.2174/0929867328666210504104419